A Phase I Study of Oral BGJ398 in Asian Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

9 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-10-19

Study Completion Date

2019-02-07

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will evaluate safety and tolerability to determine the Maximum tolerated dose (MTD) and/or Recommended dose (RD).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Study of BGB-283 in Chinese Subjects With Local Advanced or Metastatic Malignant Solid Tumor

NCT03641586

Solid Tumors

COMPLETED PHASE1

A Study to Investigate FP002 in Subjects With Advanced Malignancies

NCT05982080

Advanced Solid Tumor

RECRUITING PHASE1

A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of SSGJ-705 Monotherapy in Patients with Advanced Malignant Tumors

NCT06390774

Locally Advanced, Recurrent or Metastatic Malignancies

RECRUITING PHASE1

SG1906 for CLDN18.2-Positive Solid Tumors

NCT05857332

Locally Advanced Unresectable or Metastatic Solid Tumors

RECRUITING PHASE1

A Clinical Trial of ICP-192 in Treated Patients With Advanced Solid Tumors With FGF/FGFR Gene Alterations

NCT05372120

Advanced Solid Tumor

UNKNOWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a multi-center, open label, dose finding, phase I study of oral single agent BGJ398, administered on a continuous once and/or twice daily schedule.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Tumor With Alterations of the FGF-R

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

BGJ398

Eligible participants received oral BGJ398 once daily or twice daily. Patients may continue treatment with BGJ398 until the patient experiences unacceptable toxicity or progressive disease.

Group Type EXPERIMENTAL

BGJ398

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

BGJ398

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with advanced solid tumors with FGF-R alteration
* Eastern Cooperative Oncology Group (ECOG) performance status 0-2
* Adequate organ function